According to Eurekalert on September 4th, a crucial new review study conducted by a team of scientists, including researchers from the University of Massachusetts Amherst, identified three most effective smoking cessation strategies.
Varenicline, a prescription medication sold under brand names including Chantix and Champix; cytisine, a plant-based compound not widely available in the United States but sold as a natural health product (Cravv®) in Canada and Central and Eastern Europe, requiring a prescription in the UK; nicotine e-cigarettes. The review was conducted by the non-profit organization Cochrane Tobacco Addiction Group (CTAG) and published in the journal "Addiction," led by senior CTAG authors Jamie Hartmann-Boyce, Assistant Professor of Health Policy and Management at the University of Massachusetts Amherst School of Public Health and Health Sciences, and Jonathan Livingstone-Banks, researcher at the University of Oxford.
The review points out that the combination of these three best strategies with behavioral support, such as counseling, is most effective. Bupropion and Nicotine Replacement Therapy (NRT) are also effective, especially when NRT patches are combined with rapid forms such as gum.
The latest summary from CTAG highlights key findings from 14 Cochrane reviews published between 2021 and 2023. Three of the key reviews include:
Updated NRT review: It has been found that combining fast-acting forms of NRT (such as gum, lozenges, sprays) with NRT patches can help more people quit smoking compared to using a single form of NRT; E-cigarette review: As a dynamic systematic review, the latest update concludes that nicotine-containing e-cigarettes are more effective in increasing smoking cessation rates than NRT, with moderate certainty evidence showing higher cessation rates compared to nicotine-free e-cigarettes; 2023 Drug and E-cigarette Intervention Review: Covering all globally approved drugs and e-cigarettes for smoking cessation, the results show that nicotine e-cigarettes, varenicline, and bupropion have high certainty evidence as effective interventions, followed by combination NRT. An updated review on nicotine receptor partial agonists shows that in studies directly comparing bupropion and varenicline, the effectiveness of both in smoking cessation may not differ. The review includes 75 trials.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
